Dr Benjamin Mullish

All Stories

1. 
   Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology

   Article • Gut, June 2026, BMJ

   Dr Benjamin Mullish

2. 
   P195 Analysis of faecal protease activity demonstrates increased activity in IBD patients that is associated with disease activity

   Article • June 2026, BMJ

   Dr Benjamin Mullish

3. 
   Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort

   Article • Inflammatory Bowel Diseases, May 2026, Oxford University Press (OUP)

   Dr Benjamin Mullish

4. 
   Mo1427 IMPACT OF ABO BLOOD GROUPS ON FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIOIDES DIFFICILE INFECTION

   Article • Gastroenterology, May 2026, Elsevier

   Dr Benjamin Mullish

5. 
   Su1503 ANALYSIS OF FECAL PROTEASE ACTIVITY REVEALS INCREASED LEVELS IN IBD PATIENTS THAT ARE ASSOCIATED WITH DISEASE ACTIVITY

   Article • Gastroenterology, May 2026, Elsevier

   Dr Benjamin Mullish

6. 
   Tu1548 DISEASE PHENOTYPE AFFECTS THERAPEUTIC CHOICE IN LATE-ONSET IBD: A LARGE-SCALE ANALYSIS

   Article • Gastroenterology, May 2026, Elsevier

   Dr Benjamin Mullish

7. 
   Mo1427 IMPACT OF ABO BLOOD GROUPS ON FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIOIDES DIFFICILE INFECTION

   Article • Gastrointestinal Endoscopy, May 2026, Elsevier

   Dr Benjamin Mullish

8. 
   Su1503 ANALYSIS OF FECAL PROTEASE ACTIVITY REVEALS INCREASED LEVELS IN IBD PATIENTS THAT ARE ASSOCIATED WITH DISEASE ACTIVITY

   Article • Gastrointestinal Endoscopy, May 2026, Elsevier

   Dr Benjamin Mullish

9. 
   Tu1548 DISEASE PHENOTYPE AFFECTS THERAPEUTIC CHOICE IN LATE-ONSET IBD: A LARGE-SCALE ANALYSIS

   Article • Gastrointestinal Endoscopy, May 2026, Elsevier

   Dr Benjamin Mullish

10. 
    FRI-117 Increased serum concentration and hepatic expression of Fibroblast growth factor 19 suggests it is a potential diagnostic biomarker for alcohol-related hepatitis

    Article • Journal of Hepatology, May 2026, Elsevier

    Dr Benjamin Mullish

11. 
    THU-012 MASLD in the WHOAfrica region: prevalence and development of a simple score to detect advanced fibrosis in dysmetabolic patients

    Article • Journal of Hepatology, May 2026, Elsevier

    Dr Benjamin Mullish

12. 
    WED-041 Normal ALT values in patients with MASLD: long-term outcomes and Fib-4 performance

    Article • Journal of Hepatology, May 2026, Elsevier

    Dr Benjamin Mullish

13. 
    GI highlights from the literature

    Article • Gut, April 2026, BMJ

    Dr Benjamin Mullish

14. 
    The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus

    Article • The Lancet Gastroenterology & Hepatology, April 2026, Elsevier

    Dr Benjamin Mullish

15. 
    Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis

    Article • Alimentary Pharmacology & Therapeutics, March 2026, Wiley

    Dr Benjamin Mullish

16. 
    Defining ‘gut health’: a leap forward, but still some road to travel

    Article • Nature Reviews Gastroenterology & Hepatology, March 2026, Springer Science + Business Media

    Dr Benjamin Mullish

17. 
    A global evaluation of the use of faecal microbiota transplant (FMT)

    Article • International Journal of Infectious Diseases, March 2026, Elsevier

    Dr Benjamin Mullish

18. 
    Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis

    Article • Gastroenterology, March 2026, Elsevier

    Dr Benjamin Mullish

19. 
    Dynamics in circulating immune cell subsets after faecal microbiota transplantation for recurrent Clostridioides difficile infection

    Article • Clinical and Translational Gastroenterology, February 2026, Wolters Kluwer Health

    Dr Benjamin Mullish

20. 
    Poster Session I - A36 OPTIMIZING AND STANDARDIZING DONOR SCREENING FOR FECAL MICROBIOTA TRANSPLANTATION: A DELPHI REVIEW

    Article • Journal of the Canadian Association of Gastroenterology, February 2026, Oxford University Press (OUP)

    Dr Benjamin Mullish

21. 
    GI highlights from the literature

    Article • Gut, January 2026, BMJ

    Dr Benjamin Mullish

22. 
    P0841 Disease phenotype affects therapeutic choice in late-onset IBD: a large-scale analysis

    Article • Journal of Crohn s and Colitis, January 2026, Oxford University Press (OUP)

    Dr Benjamin Mullish

23. 
    P1158 Ethnic differences in medication adherence and illness perception in Inflammatory Bowel Disease: A comparative study of White and South Asian patients

    Article • Journal of Crohn s and Colitis, January 2026, Oxford University Press (OUP)

    Dr Benjamin Mullish

24. 
    Improving efficacy without increasing side effects? Exploring the impact of a novel GLP-1-glucagon dual receptor agonist upon metabolic dysfunction-associated steatohepatitis.

    Article • Gastroenterology, January 2026, Elsevier

    Dr Benjamin Mullish

25. 
    Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials

    Article • BMJ Open, December 2025, BMJ

    Dr Benjamin Mullish

26. 
    Towards optimising and standardising donor screening for faecal microbiota transplantion

    Article • Gut, November 2025, BMJ

    Dr Benjamin Mullish

27. 
    Microbiota transplants: the concept of ‘microbiome mismatching’ explored

    Article • Signal Transduction and Targeted Therapy, November 2025, Springer Science + Business Media

    Dr Benjamin Mullish

28. 
    A practical approach to nutrition in people with cirrhosis

    Article • Frontline Gastroenterology, November 2025, BMJ

    Dr Benjamin Mullish

29. 
    A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities

    Article • EClinicalMedicine, November 2025, Elsevier

    Dr Benjamin Mullish

30. 
    GI highlights from the literature

    Article • Gut, October 2025, BMJ

    Dr Benjamin Mullish

31. 
    S1572 Evaluation of Rectal Swabs as a Viable Alternative to Faecal Sampling for Calprotectin Measurement in IBD Patients

    Article • The American Journal of Gastroenterology, October 2025, Wolters Kluwer Health

    Dr Benjamin Mullish

32. 
    The impact of three distinct probiotic supplements on the gut microbiota and its metabolites in healthy adults

    Article • Beneficial Microbes, September 2025, De Gruyter

    Dr Benjamin Mullish

33. 
    The emerging role of the gut microbiota in vaccination responses

    Article • Gut Microbes, August 2025, Taylor & Francis

    Dr Benjamin Mullish

34. 
    Exploring the differential impact of steatotic liver disease phenotypes upon clinical outcomes

    Article • Gastroenterology, August 2025, Elsevier

    Dr Benjamin Mullish

35. 
    Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service

    Article • Journal of Hospital Infection, August 2025, Elsevier

    Dr Benjamin Mullish

36. 
    Deciphering the microbiome–metabolome landscape of an inflammatory bowel disease inception cohort

    Article • Gut Microbes, July 2025, Taylor & Francis

    Dr Benjamin Mullish

37. 
    Correction to: Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy

    Article • Clinical Infectious Diseases, July 2025, Oxford University Press (OUP)

    Dr Benjamin Mullish

38. 
    Vancomycin-resistant enterococci utilise antibiotic-enriched nutrients for intestinal colonisation

    Article • Nature Communications, July 2025, Springer Science + Business Media

    Dr Benjamin Mullish

39. 
    GI highlights from the literature

    Article • Gut, July 2025, BMJ

    Dr Benjamin Mullish

40. 
    Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic hepatitis B

    Article • Clinical Gastroenterology and Hepatology, July 2025, Elsevier

    Dr Benjamin Mullish

41. 
    Non-antimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer?

    Article • Clinical Microbiology and Infection, July 2025, Elsevier

    Dr Benjamin Mullish

42. 
    Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging

    Article • Frontline Gastroenterology, June 2025, BMJ

    Dr Benjamin Mullish

43. 
    The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2025, Endocrine Society

    Dr Benjamin Mullish

44. 
    Interplay of constipation, intestinal barrier dysfunction and fungal exposome in aetiopathogenesis of Parkinson’s disease: hypothesis with supportive data

    Article • Biochemical Journal, June 2025, Portland Press Ltd.

    Dr Benjamin Mullish

45. 
    127: A LARGE-SCALE COMPARATIVE ANALYSIS OF ETHNIC DIFFERENCES IN CLINICAL RESPONSE TO IBD THERAPIES IN THE UK.

    Article • Gastroenterology, May 2025, Elsevier

    Dr Benjamin Mullish

46. 
    Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy

    Article • Clinical Infectious Diseases, April 2025, Oxford University Press (OUP)

    Dr Benjamin Mullish

47. 
    Deciphering the microbiome–metabolome landscape of an inflammatory bowel disease inception cohort

    Article • March 2025, Springer Science + Business Media

    Dr Benjamin Mullish

48. 
    The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort

    Article • March 2025, Cold Spring Harbor Laboratory Press

    Dr Benjamin Mullish

49. 
    GI highlights from the literature

    Article • Gut, March 2025, BMJ

    Dr Benjamin Mullish

50. 
    FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial

    Article • BMJ Open, January 2025, BMJ

    Dr Benjamin Mullish

51. 
    P0787 A large-scale comparison of clinical response to IBD therapies in white and non-white ethnicities

    Article • Journal of Crohn s and Colitis, January 2025, Oxford University Press (OUP)

    Dr Benjamin Mullish

52. 
    Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures

    Article • Journal of Crohn s and Colitis, December 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

53. 
    Vancomycin-resistantEnterococcuscolonise the antibiotic-treated intestine by occupying distinct nutrient- and metabolite-defined intestinal niches

    Article • December 2024, Cold Spring Harbor Laboratory Press

    Dr Benjamin Mullish

54. 
    Diverse phenotypes, consistent treatment: a study of 30,997 South Asian and White IBD patients using the UK IBD BioResource

    Article • Journal of Crohn s and Colitis, December 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

55. 
    International consensus statement on microbiome testing in clinical practice

    Article • The Lancet Gastroenterology & Hepatology, December 2024, Elsevier

    Dr Benjamin Mullish

56. 
    IntestinalMicrobiota Transplant Prior toAllogeneicStem CellTransplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial

    Article • BMJ Open, December 2024, BMJ

    Dr Benjamin Mullish

57. 
    GI highlights from the literature

    Article • Gut, November 2024, BMJ

    Dr Benjamin Mullish

58. 
    Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

    Article • Gut Microbes, November 2024, Taylor & Francis

    Dr Benjamin Mullish

59. 
    Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial

    Article • Blood, November 2024, American Society of Hematology

    Dr Benjamin Mullish

60. 
    New agonists of the incretin/glucagon system for the treatment of metabolic dysfunction-associated steatohepatitis

    Article • Gastroenterology, November 2024, Elsevier

    Dr Benjamin Mullish

61. 
    Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community

    Article • PLOS One, September 2024, PLOS

    Dr Benjamin Mullish

62. 
    Preface to Special Edition: Microbiome, Inflammation and Cancer

    Article • Best Practice & Research Clinical Gastroenterology, September 2024, Elsevier

    Dr Benjamin Mullish

63. 
    GI highlights from the literature

    Article • Gut, August 2024, BMJ

    Dr Benjamin Mullish

64. 
    3D printed rectal swabs for assessing the gut microbiome, metabolome and inflammation

    Article • Scientific Reports, July 2024, Springer Science + Business Media

    Dr Benjamin Mullish

65. 
    Inflammation, oxidative stress and gut microbiome perturbation: A narrative review of mechanisms and treatment of the alcohol hangover

    Article • Alcohol Clinical and Experimental Research, July 2024, Wiley

    Dr Benjamin Mullish

66. 
    Alcohol-Associated liver disease: Emerging therapeutic strategies

    Article • Hepatology, June 2024, Wolters Kluwer Health

    Dr Benjamin Mullish

67. 
    A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

    Article • Hepatology International, June 2024, Springer Science + Business Media

    Dr Benjamin Mullish, Dr. Federico Ravaioli

68. 
    FRI-215-YI MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

69. 
    FRI-286 Muscle function and walking time are associated with better quality of life in MASLD patients

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

70. 
    OS-070 Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish, Dr Vishal C Patel

71. 
    THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish, Dr Vishal C Patel

72. 
    WED-546 Evidence of gut microbiome differences in post-menopausal females with metabolic dysfunction-associated liver disease compared to pre-menopausal females and males

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

73. 
    P126 Gut microbiota composition and functionality in a thiopurine-naïve cohort of inflammatory bowel disease (IBD) can differentiate between clinical outcomes

    Article • June 2024, BMJ

    Dr Benjamin Mullish

74. 
    P61 Ethnic differences in ulcerative colitis: a study of 15,053 South Asian and white patients using the UK IBD bioresource

    Article • June 2024, BMJ

    Dr Benjamin Mullish

75. 
    Decision

    Article • May 2024, Taylor & Francis

    Dr Benjamin Mullish

76. 
    The Role of Fecal Microbiota Transplantation in the Treatment of Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease

    Article • May 2024, Taylor & Francis

    Dr Benjamin Mullish

77. 
    Authors' reply to letter: He who controls Clostridia and Bacteroidia controls the gut microbiome: The concept of targeted probiotics to restore the balance of keystone taxa in irritable bowel syndrome

    Article • Neurogastroenterology & Motility, May 2024, Wiley

    Dr Benjamin Mullish

78. 
    GI highlights from the literature

    Article • Gut, May 2024, BMJ

    Dr Benjamin Mullish

79. 
    Mo1870 CONSISTENT APPROACH TO IBD TREATMENT ACROSS SOUTH ASIAN AND WHITE ETHNICITIES IN THE UK DESPITE PHENOTYPIC VARIATIONS: A STUDY OF 33,157 PATIENTS USING THE IBD BIORESOURCE

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

80. 
    Sa1871 THE COMPOSITION AND FUNCTION OF THE GUT MICROBIOTA IN A TREATMENT NAIVE INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) CAN ACCURATELY DIFFERENTIATE IBD PHENOTYPE.

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

81. 
    Sa1889 3D PRINTED RECTAL SWABS FOR ASSESSING THE GUT MICROBIOME, METABOLOME, AND INFLAMMATION

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

82. 
    Sa1927 ANTIBIOTIC TREATMENT PROMOTES THE INTESTINAL COLONISATION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS BY KILLING MEMBERS OF THE GUT MICROBIOTA AND DECREASING NUTRIENT COMPETITION

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

83. 
    Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

84. 
    The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

85. 
    The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridioides difficileinfection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society...

    Article • Gut, April 2024, BMJ

    Dr Benjamin Mullish

86. 
    The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS...

    Article • Journal of Hospital Infection, April 2024, Elsevier

    Dr Benjamin Mullish

87. 
    Lyophilized fecal microbiome transfer for primary Clostridioides difficile infection: a multicenter randomized controlled trial (DONATE Study)

    Article • Open Research Europe, March 2024, Faculty of 1000, Ltd.

    Dr Benjamin Mullish

88. 
    Overview of the second edition of the joint British Society of Gastroenterology and Healthcare Infection Society faecal microbiota transplant guidelines, 2024

    Article • Journal of Hospital Infection, March 2024, Elsevier

    Dr Benjamin Mullish

89. 
    The beneficial hepatic effects of glucagon‐like peptide 1 receptor agonists in patients with diabetes and metabolic dysfunction‐associated steatotic liver disease are independent of weight loss

    Article • Liver International Communications, March 2024, Wiley

    Dr Benjamin Mullish

90. 
    GI highlights from the literature

    Article • Gut, February 2024, BMJ

    Dr Benjamin Mullish

91. 
    A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females

    Article • Neurogastroenterology & Motility, January 2024, Wiley

    Dr Benjamin Mullish

92. 
    Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

    Article • Gut Microbes, January 2024, Taylor & Francis

    Dr Benjamin Mullish

93. 
    Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial

    Article • RMD Open, January 2024, BMJ

    Dr Benjamin Mullish

94. 
    OP07 Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResource

    Article • Journal of Crohn s and Colitis, January 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

95. 
    P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis

    Article • Journal of Crohn s and Colitis, January 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

96. 
    Risk Factors for Liver Cancer and Chronic Liver Disease-related Death: Are Sugar Substitutes Better Than the Real Thing?

    Article • Gastroenterology, January 2024, Elsevier

    Dr Benjamin Mullish

97. 
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients

    Article • Journal of Hepatology, January 2024, Elsevier

    Dr Benjamin Mullish

98. 
    Liver sinusoidal cells in the diagnosis and treatment of liver diseases: Role of hepatic stellate cells

    Article • January 2024, Elsevier

    Dr Benjamin Mullish

99. 
    Evaluating Protocols for Reproducible Targeted Metabolomics by NMR

    Article • The Analyst, January 2024, Royal Society of Chemistry

    Dr Benjamin Mullish, Dr Robert Powers

100. 
     Pharmacotherapy in Managing Alcohol-Use Disorder

     Article • Gastroenterology, December 2023, Elsevier

     Dr Benjamin Mullish

101. 
     The role of faecal microbiota transplantation in chronic noncommunicable disorders

     Article • Journal of Autoimmunity, December 2023, Elsevier

     Dr Benjamin Mullish

102. 
     GI highlights from the literature

     Article • Gut, November 2023, BMJ

     Dr Benjamin Mullish

103. 
     Gut microbiota and immunotherapy of renal cell carcinoma

     Article • Human Vaccines & Immunotherapeutics, November 2023, Taylor & Francis

     Dr Benjamin Mullish

104. 
     Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

     Article • Nature Medicine, November 2023, Springer Science + Business Media

     Dr Benjamin Mullish, Jeremy Paul Burton

105. 
     THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD

     Article • Journal of the Endocrine Society, October 2023, Endocrine Society

     Dr Benjamin Mullish

106. 
     Alcohol Minimum Unit Pricing Reduces Alcohol-Specific Hospitalizations and Deaths

     Article • Gastroenterology, October 2023, Elsevier

     Dr Benjamin Mullish

107. 
     Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA<...

     Article • ACR Open Rheumatology, September 2023, Wiley

     Dr Benjamin Mullish

108. 
     A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies

     Article • Liver International, September 2023, Wiley

     Dr Benjamin Mullish

109. 
     O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease

     Article • September 2023, BMJ

     Dr Benjamin Mullish

110. 
     P18 A 5 sit-to-stand test may identify NAFLD patients at higher risk for worse clinical outcomes

     Article • September 2023, BMJ

     Dr Benjamin Mullish

111. 
     P26 Exploring the association between quality of life, diet, physical activity, and binge eating disorder in NAFLD patients in a tertiary centre of care

     Article • September 2023, BMJ

     Dr Benjamin Mullish

112. 
     Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites

     Article • Nature Communications, August 2023, Springer Science + Business Media

     Dr Benjamin Mullish

113. 
     GI highlights from the literature

     Article • Gut, August 2023, BMJ

     Dr Benjamin Mullish

114. 
     Maternal Diet and Risk of Obesity in Offspring

     Article • Gastroenterology, August 2023, Elsevier

     Dr Benjamin Mullish

115. 
     Faecal microbiota transplant restores intestinal barrier function and augments ammonia metabolism in patients with cirrhosis: a randomised single-blind placebo-controlled trial

     Article • July 2023, Research Square

     Dr Benjamin Mullish

116. 
     Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

     Article • Nature Medicine, July 2023, Springer Science + Business Media

     Dr Benjamin Mullish, Jeremy Paul Burton

117. 
     SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

     Article • Nature Medicine, July 2023, Springer Science + Business Media

     Dr Benjamin Mullish, Dr Stephen P McAdoo, Dr dan Wootton

118. 
     Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease

     Article • Journal of Hepatology, June 2023, Elsevier

     Dr Benjamin Mullish

119. 
     P79 COVID-19 vaccine-induced antibody response is associated with oral microbiota composition in patients with inflammatory bowel disease, cirrhosis, and liver transplantation

     Article • June 2023, BMJ

     Dr Benjamin Mullish

120. 
     P325 Colonoscopy surveillance in primary sclerosing cholangitis patients during the COVID-19 pandemic – a tertiary centre experience

     Article • June 2023, BMJ

     Dr Benjamin Mullish

121. 
     Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial

     Article • Journal of Hepatology, June 2023, Elsevier

     Dr Benjamin Mullish

122. 
     Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial

     Article • Journal of Hepatology, June 2023, Elsevier

     Dr Benjamin Mullish

123. 
     Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease

     Article • Journal of Hepatology, June 2023, Elsevier

     Dr Benjamin Mullish

124. 
     Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients

     Article • Journal of Hepatology, June 2023, Elsevier

     Dr Benjamin Mullish

125. 
     Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation

     Article • Heliyon, June 2023, Elsevier

     Dr Benjamin Mullish

126. 
     The Impact of Proportional Dietary Carbohydrate and Fat Content on Type 2 Diabetes and NAFLD

     Article • Gastroenterology, June 2023, Elsevier

     Dr Benjamin Mullish

127. 
     POS0423 PLASMA METABOLOMIC PROFILES OF PATIENTS WITH ACTIVE PERIPHERAL PSORIATIC ARTHRITIS CAN DIFFERENTIATE TREATMENT RESPONDERS FROM FAILURES: EXPLORATORY FINDINGS FROM THE FLORA TRIAL

     Article • May 2023, BMJ

     Dr Benjamin Mullish

128. 
     A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease

     Article • Movement Disorders, May 2023, Wiley

     Dr Benjamin Mullish

129. 
     Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy

     Article • Antibiotics, May 2023, MDPI AG

     Dr Benjamin Mullish

130. 
     GI highlights from the literature

     Article • Gut, May 2023, BMJ

     Dr Benjamin Mullish

131. 
     Increased risk of cirrhosis in post-menopausal women with NAFLD

     Article • Endocrine Abstracts, May 2023, Bioscientifica

     Dr Benjamin Mullish

132. 
     Tu1866 SALIVARY MICROBIOTA COMPOSITION IS ASSOCIATED WITH ANTIBODY RESPONSE FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE, CIRRHOSIS AND LIVER TRANSPLANTATION

     Article • Gastroenterology, May 2023, Elsevier

     Dr Benjamin Mullish

133. 
     Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective

     Article • Nutrients, April 2023, MDPI AG

     Dr Benjamin Mullish

134. 
     Screening for NAFLD—Current Knowledge and Challenges

     Article • Metabolites, April 2023, MDPI AG

     Dr Benjamin Mullish

135. 
     The gastrointestinal status of healthy adults: a post hoc assessment of the impact of three distinct probiotics

     Article • Beneficial Microbes, April 2023, Wageningen Academic Publishers

     Dr Benjamin Mullish

136. 
     GI highlights from the literature

     Article • Gut, April 2023, BMJ

     Dr Benjamin Mullish

137. 
     Antibiotics promote intestinal growth of carbapenem-resistantEnterobacteriaceaeby enriching nutrients and depleting microbial metabolites

     Article • March 2023, Cold Spring Harbor Laboratory Press

     Dr Benjamin Mullish

138. 
     Prospective evaluation of screening strategies for NAFLD in people with type-2 diabetes mellitus in the community

     Article • Digestive and Liver Disease, March 2023, Elsevier

     Dr Benjamin Mullish

139. 
     Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease

     Article • International Journal of Molecular Sciences, February 2023, MDPI AG

     Dr Benjamin Mullish

140. 
     The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients

     Article • EBioMedicine, February 2023, Elsevier

     Dr Benjamin Mullish

141. 
     Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition

     Article • Scientific Reports, January 2023, Springer Science + Business Media

     Dr Benjamin Mullish

142. 
     GI highlights from the literature

     Article • Gut, January 2023, BMJ

     Dr Benjamin Mullish

143. 
     Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome

     Article • Clinical and Translational Medicine, January 2023, Wiley

     Dr Benjamin Mullish

144. 
     Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply

     Article • Alimentary Pharmacology & Therapeutics, December 2022, Wiley

     Dr Benjamin Mullish

145. 
     Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans

     Article • Nutrients, December 2022, MDPI AG

     Dr Benjamin Mullish, Professor Keith A Crandall

146. 
     GI highlights from the literature

     Article • Gut, November 2022, BMJ

     Dr Benjamin Mullish

147. 
     627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy

     Article • November 2022, BMJ

     Dr Benjamin Mullish

148. 
     614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

     Article • November 2022, BMJ

     Dr Benjamin Mullish

149. 
     Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel

     Article • The Lancet Gastroenterology & Hepatology, November 2022, Elsevier

     Dr Benjamin Mullish

150. 
     Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection

     Article • Alimentary Pharmacology & Therapeutics, October 2022, Wiley

     Dr Benjamin Mullish

151. 
     Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

     Article • October 2022, Research Square

     Dr Benjamin Mullish, Dr Emmanouil Tsochatzis

152. 
     UEG Week 2022 Poster Presentations

     Article • United European Gastroenterology Journal, October 2022, Wiley

     Dr Benjamin Mullish

153. 
     Polymorphic microbes: a new emerging hallmark of cancer

     Article • Trends in Microbiology, September 2022, Elsevier

     Dr Benjamin Mullish

154. 
     New insights into host‐microbiome crosstalk in psoriatic skin

     Article • Clinical and Translational Discovery, September 2022, Wiley

     Dr Benjamin Mullish

155. 
     Recent Findings in the Gut-Liver Axis and Associated Disease Therapy

     Article • EMJ Hepatology, August 2022, European Medical Group

     Dr Benjamin Mullish

156. 
     GI highlights from the literature

     Article • Gut, August 2022, BMJ

     Dr Benjamin Mullish

157. 
     Further Insights Into the Impact of Bariatric Surgery on the Progression of Nonalcoholic Fatty Liver Disease

     Article • Gastroenterology, August 2022, Elsevier

     Dr Benjamin Mullish

158. 
     Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

     Article • International Journal of Molecular Sciences, July 2022, MDPI AG

     Dr Benjamin Mullish

159. 
     A study evaluating outcomes of a virtual specialist liver cirrhosis clinic

     Article • Journal of Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

160. 
     Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus

     Article • Journal of Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

161. 
     Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls

     Article • Journal of Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

162. 
     Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD

     Article • Journal of Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

163. 
     Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study

     Article • Journal of Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

164. 
     Intestinal microbiota transplantation: do not forget the metabolites

     Article • The Lancet Gastroenterology & Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

165. 
     Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases

     Article • Journal of Hepatology, July 2022, Elsevier

     Dr Benjamin Mullish

166. 
     Fecal bile acid profiles predict recurrence in patients with primary Clostridioides difficile infection

     Article • June 2022, Cold Spring Harbor Laboratory Press

     Dr Benjamin Mullish

167. 
     GI highlights from the literature

     Article • Gut, June 2022, BMJ

     Dr Benjamin Mullish

168. 
     P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function

     Article • June 2022, BMJ

     Dr Benjamin Mullish

169. 
     The gut microbiota and metabolome is associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients

     Article • May 2022, Research Square

     Dr Benjamin Mullish

170. 
     Identifying transient and stable bacteria- metabolite interactions from longitudinal multi-omics data

     Article • May 2022, Research Square

     Dr Benjamin Mullish

171. 
     Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome

     Article • BMC Gastroenterology, May 2022, Springer Science + Business Media

     Dr Benjamin Mullish

172. 
     643: CLINICAL AND ECONOMICAL EVALUATION OF COMMUNITY-BASED PREVENTATIVE SCREENING STRATEGIES FOR NON-ALCOHOLIC FATTY LIVER DISEASE

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

173. 
     681: FACTORS ASSOCIATED WITH INCREASED GUT PERMEABILITY AND SEVERITY OF LIVER DISEASE IN DIABETIC PATIENTS WITH NAFLD

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

174. 
     894: RELATIVE CHANGE OF ENTEROCOCCUS FAECIUM, SELECTED COMMENSAL BACTERIA AND CYTOKINES ARE SEEN IN PATIENTS COLONIZED WITH MULTIDRUG-RESISTANT ORGANISMS WHO UNDERGO INTESTINAL MICROBIOTA TRANSPLANTATION.

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

175. 
     Mo1589: IMPACT ON GUT MICROBIAL METABOLITES FROM A 6-MONTH DOUBLEBLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF FECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE PERIPHERAL PSORIATIC ARTHRITIS

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

176. 
     Sa1657: NEW LINKS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOME SUGGEST A STRONGER ROLE OF THE GUT-JOINT AXIS

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

177. 
     Su1601: INTESTINAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIODIOIDES DIFFICILE INFECTION IS ASSOCIATED WITH RESTORATION OF MICROBIAL ARYLSULFATASES AND SULFATIDE DEGRADATION

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

178. 
     Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

179. 
     Tu1312: EXAMINING THE CORRELATION OF HISTOLOGICAL FEATURES OF NAFLD WITH A POLYMETABOLIC RISK SCORE FOR PREDICTING PATIENTS WITH NAFLD

     Article • Gastroenterology, May 2022, Elsevier

     Dr Benjamin Mullish

180. 
     Impact of gastrointestinal surgery upon the gut microbiome: A systematic review

     Article • Surgery, May 2022, Elsevier

     Dr Benjamin Mullish

181. 
     How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection

     Article • Clinical Microbiology and Infection, April 2022, Elsevier

     Dr Benjamin Mullish

182. 
     GI highlights from the literature

     Article • Gut, March 2022, BMJ

     Dr Benjamin Mullish

183. 
     The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases

     Article • Gut Microbes, March 2022, Taylor & Francis

     Dr Benjamin Mullish

184. 
     Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition

     Article • March 2022, Research Square

     Dr Benjamin Mullish

185. 
     The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease

     Article • International Journal of Molecular Sciences, January 2022, MDPI AG

     Dr Benjamin Mullish

186. 
     The potential of fecal microbiota transplantation in oncology

     Article • Trends in Microbiology, January 2022, Elsevier

     Dr Benjamin Mullish

187. 
     Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?

     Article • World Journal of Hepatology, December 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

     Dr Benjamin Mullish

188. 
     GI highlights from the literature

     Article • Gut, December 2021, BMJ

     Dr Benjamin Mullish

189. 
     A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection

     Article • Cells, November 2021, MDPI AG

     Dr Payton Tung On Yau, Dr Benjamin Mullish

190. 
     Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease

     Article • Alimentary Pharmacology & Therapeutics, November 2021, Wiley

     Dr Benjamin Mullish

191. 
     Clostridioides difficile: innovations in target discovery and potential for therapeutic success

     Article • Expert Opinion on Therapeutic Targets, November 2021, Taylor & Francis

     Dr Benjamin Mullish

192. 
     Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD)

     Article • Endocrine Abstracts, October 2021, Bioscientifica

     Dr Benjamin Mullish

193. 
     Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series

     Article • American Journal of Hematology, October 2021, Wiley

     Dr Benjamin Mullish

194. 
     GI highlights from the literature

     Article • Gut, October 2021, BMJ

     Dr Benjamin Mullish

195. 
     The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey

     Article • The Lancet Regional Health - Europe, October 2021, Elsevier

     Dr Benjamin Mullish

196. 
     Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use

     Article • European Medical Journal, September 2021, European Medical Group

     Dr Benjamin Mullish

197. 
     Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation

     Article • Frontiers in Cellular and Infection Microbiology, August 2021, Frontiers

     Dr Benjamin Mullish

198. 
     GI highlights from the literature

     Article • Gut, August 2021, BMJ

     Dr Benjamin Mullish

199. 
     Binge‐eating disorder is associated with an unfavorable body mass composition in patients with non‐alcoholic fatty liver disease

     Article • International Journal of Eating Disorders, July 2021, Wiley

     Dr Benjamin Mullish

200. 
     Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India

     Article • Microorganisms, July 2021, MDPI AG

     Dr Payton Tung On Yau, Dr Benjamin Mullish

201. 
     Rapid resolution of COVID-19 after faecal microbiota transplantation

     Article • Gut, July 2021, BMJ

     Dr Benjamin Mullish

202. 
     GI highlights from the literature

     Article • Gut, May 2021, BMJ

     Dr Benjamin Mullish

203. 
     739 DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE

     Article • Gastroenterology, May 2021, Elsevier

     Dr Benjamin Mullish

204. 
     811 FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL

     Article • Gastroenterology, May 2021, Elsevier

     Dr Benjamin Mullish

205. 
     Fr571 A DISTINCTIVE SIGNATURE OF FECAL BILE ACIDS AND OTHER NOVEL METABOLITES ACCOMPANYING RECURRENCE AFTER PRIMARY CLOSTRIDIOIDES DIFFICILE INFECTION

     Article • Gastroenterology, May 2021, Elsevier

     Dr Benjamin Mullish

206. 
     Fr573 ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE

     Article • Gastroenterology, May 2021, Elsevier

     Dr Benjamin Mullish

207. 
     Sa022 A HIGH-FIBER LOW-FAT DIET INCREASES FECAL LEVELS OF LITHOCHOLIC ACID DERIVATIVE 3-KETOCHOLANIC ACID

     Article • Gastroenterology, May 2021, Elsevier

     Dr Benjamin Mullish

208. 
     Su541 RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION

     Article • Gastroenterology, May 2021, Elsevier

     Dr Benjamin Mullish

209. 
     SARS-CoV-2 vaccines and donor recruitment for FMT

     Article • The Lancet Gastroenterology & Hepatology, April 2021, Elsevier

     Dr Benjamin Mullish

210. 
     Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice

     Article • Journal of Gastrointestinal and Liver Diseases, March 2021, Romanian Society of Gastroenterology and Heptatology

     Dr Benjamin Mullish

211. 
     Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections

     Article • Frontline Gastroenterology, March 2021, BMJ

     Dr Benjamin Mullish

212. 
     GI highlights from the literature

     Article • Gut, March 2021, BMJ

     Dr Benjamin Mullish

213. 
     Fecal Microbiota Transplantation: The Evolving Risk Landscape

     Article • The American Journal of Gastroenterology, February 2021, Wolters Kluwer Health

     Dr Benjamin Mullish

214. 
     Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity

     Article • HORMONES, January 2021, Springer Science + Business Media

     Dr Benjamin Mullish

215. 
     Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults

     Article • Scientific Reports, January 2021, Springer Science + Business Media

     Dr Benjamin Mullish

216. 
     Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?

     Article • Gut Microbes, January 2021, Taylor & Francis

     Dr Benjamin Mullish

217. 
     NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials

     Article • Journal of Hepatology, January 2021, Elsevier

     Dr Benjamin Mullish

218. 
     The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection

     Article • Therapeutic Advances in Gastroenterology, January 2021, SAGE Publications

     Dr Benjamin Mullish

219. 
     Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

     Article • SSRN Electronic Journal, January 2021, Elsevier

     Dr Benjamin Mullish

220. 
     P307 FMT-associated alterations in the TCR repertoire of patients with severe or fulminant clostridioides difficile infection

     Article • January 2021, BMJ

     Dr Benjamin Mullish

221. 
     Non-Alcoholic Fatty Liver Disease and Vascular Disease

     Article • Current Vascular Pharmacology, December 2020, Bentham Science Publishers

     Dr Benjamin Mullish

222. 
     Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection

     Article • Gut Microbes, December 2020, Taylor & Francis

     Prof. Marcin Frankowski, Dr Benjamin Mullish

223. 
     The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010-O173)

     Article • British Journal of Pharmacology, December 2020, Springer Science + Business Media

     Dr Benjamin Mullish

224. 
     Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis

     Article • EClinicalMedicine, December 2020, Elsevier

     Dr Benjamin Mullish

225. 
     GI highlights from the literature

     Article • Gut, November 2020, BMJ

     Dr Benjamin Mullish

226. 
     Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection

     Article • Inflammatory Bowel Diseases, November 2020, Oxford University Press (OUP)

     Dr Benjamin Mullish

227. 
     Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection

     Article • Gastroenterology, November 2020, Elsevier

     Dr Benjamin Mullish

228. 
     A Guide to the Gut Microbiome and its Relevance to Critical Care

     Article • British Journal of Nursing, October 2020, Mark Allen Group

     Dr Benjamin Mullish

229. 
     Letter: intestinal microbiota transfer—updating the nomenclature to increase acceptability

     Article • Alimentary Pharmacology & Therapeutics, October 2020, Wiley

     Dr Benjamin Mullish

230. 
     Reply to Woodworth, et al.

     Article • Clinical Infectious Diseases, October 2020, Oxford University Press (OUP)

     Dr Benjamin Mullish

231. 
     In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19

     Article • PLOS One, October 2020, PLOS

     Dr Benjamin Mullish

232. 
     Abstract Supplement ACR Convergence 2020

     Article • Arthritis & Rheumatology, October 2020, Wiley

     Dr Benjamin Mullish

233. 
     S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection

     Article • The American Journal of Gastroenterology, October 2020, Wolters Kluwer Health

     Dr Benjamin Mullish

234. 
     Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites

     Article • Gut Microbes, September 2020, Taylor & Francis

     Dr Benjamin Mullish

235. 
     Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?

     Article • Clinical Immunology, September 2020, Elsevier

     Dr Benjamin Mullish

236. 
     Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders

     Article • Future Microbiology, August 2020, Future Medicine

     Dr Benjamin Mullish

237. 
     High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease

     Article • Clinical Gastroenterology and Hepatology, August 2020, Elsevier

     Dr Benjamin Mullish

238. 
     Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis

     Article • Journal of Hepatology, August 2020, Elsevier

     Dr Benjamin Mullish, Dr Vishal C Patel

239. 
     Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms

     Article • Clinical Infectious Diseases, July 2020, Oxford University Press (OUP)

     Dr Benjamin Mullish

240. 
     Letter: faecal microbiota transplantation for IBS

     Article • Alimentary Pharmacology & Therapeutics, July 2020, Wiley

     Dr Benjamin Mullish

241. 
     Letter: liver disease and COVID‐19—not the perfect storm

     Article • Alimentary Pharmacology & Therapeutics, July 2020, Wiley

     Dr Benjamin Mullish

242. 
     GI highlights from the literature

     Article • Gut, July 2020, BMJ

     Dr Benjamin Mullish

243. 
     Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

     Article • Gut, July 2020, BMJ

     Dr Benjamin Mullish

244. 
     Correction to Lancet Gastroenterol Hepatol 2020; 5: 430–31

     Article • The Lancet Gastroenterology & Hepatology, June 2020, Elsevier

     Dr Benjamin Mullish

245. 
     1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION

     Article • Gastroenterology, May 2020, Elsevier

     Dr Benjamin Mullish

246. 
     121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION

     Article • Gastroenterology, May 2020, Elsevier

     Dr Benjamin Mullish

247. 
     644 IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION

     Article • Gastroenterology, May 2020, Elsevier

     Dr Benjamin Mullish

248. 
     Mo1939 TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING SEQUENTIAL FMT TREATMENT IN PATIENTS WITH SEVERE OR FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION

     Article • Gastroenterology, May 2020, Elsevier

     Dr Benjamin Mullish

249. 
     Sa1923 IDENTIFICATION OF NEW ASSOCIATIONS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOTA, A PHENOMIC STUDY

     Article • Gastroenterology, May 2020, Elsevier

     Dr Benjamin Mullish

250. 
     Tu1909 IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON PREVENTION OF METABOLIC SYNDROME AMONG PATIENTS WITH OBESITY

     Article • Gastroenterology, May 2020, Elsevier

     Dr Benjamin Mullish

251. 
     Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

     Article • The Lancet Gastroenterology & Hepatology, May 2020, Elsevier

     Dr Benjamin Mullish

252. 
     Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?

     Article • Gut, April 2020, BMJ

     Dr Benjamin Mullish

253. 
     GI highlights from the literature

     Article • Gut, April 2020, BMJ

     Dr Benjamin Mullish

254. 
     Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients

     Article • Clinical Gastroenterology and Hepatology, April 2020, Elsevier

     Dr Benjamin Mullish

255. 
     A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

     Article • Scientific Reports, March 2020, Springer Science + Business Media

     Dr Benjamin Mullish

256. 
     GI highlights from the literature

     Article • Gut, March 2020, BMJ

     Dr Benjamin Mullish

257. 
     Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy

     Article • Scientific Reports, March 2020, Springer Science + Business Media

     Dr Benjamin Mullish

258. 
     The gut microbiome: what every gastroenterologist needs to know

     Article • Frontline Gastroenterology, February 2020, BMJ

     Dr Benjamin Mullish

259. 
     Case-control study of recurrent Extended-Spectrum Beta Lactamase Enterobacteriaceae Urinary Tract Infections (ESBL UTIs): the management challenges

     Article • Access Microbiology, February 2020, Society for General Microbiology

     Dr Benjamin Mullish

260. 
     Cohort study of Faecal Microbiota Transplantation for patient’s colonised with MDROs - successful prevention of invasive disease despite low decolonisation rates

     Article • Access Microbiology, February 2020, Society for General Microbiology

     Dr Benjamin Mullish

261. 
     Faculty Opinions recommendation of Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection.

     Article • January 2020, F1000Research

     Dr Benjamin Mullish

262. 
     Faecal microbiota transplantations and urinary tract infections – Authors' reply

     Article • The Lancet, January 2020, Elsevier

     Dr Benjamin Mullish

263. 
     Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease

     Article • Therapeutic Advances in Gastroenterology, January 2020, SAGE Publications

     Dr Benjamin Mullish

264. 
     P844 Higher proportions of genera and species in the Firmicutes phylum are associated with a healthy pouch compared with patients with chronic pouchitis

     Article • Journal of Crohn s and Colitis, January 2020, Oxford University Press (OUP)

     Dr Benjamin Mullish

265. 
     The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?

     Article • Therapeutic Advances in Gastroenterology, January 2020, SAGE Publications

     Dr Benjamin Mullish

266. 
     Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

     Article • Immunology, November 2019, Wiley

     Dr Benjamin Mullish

267. 
     Antibiotic therapy and outcome from immune-checkpoint inhibitors

     Article • Journal for ImmunoTherapy of Cancer, November 2019, BMJ

     Dr Benjamin Mullish

268. 
     Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non‐alcoholic fatty liver disease—authors' reply

     Article • Alimentary Pharmacology & Therapeutics, October 2019, Wiley

     Dr Benjamin Mullish

269. 
     185 Evaluating Dynamics of Bile Acid Metabolism to Predict Recurrence of Clostridioides difficile Infection

     Article • The American Journal of Gastroenterology, October 2019, Wolters Kluwer Health

     Dr Benjamin Mullish

270. 
     837 Short Chain Fatty Acid Profiles Are Altered by Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection

     Article • The American Journal of Gastroenterology, October 2019, Wolters Kluwer Health

     Dr Benjamin Mullish

271. 
     Posters (Abstracts 289–2348)

     Article • Hepatology, October 2019, Wolters Kluwer Health

     Dr Benjamin Mullish

272. 
     Guidelines - Stool banking for faecal microbiota transplantation in clinical practice

     Article • Gut, September 2019, BMJ

     Giovanni Cammarota, Dr Benjamin Mullish

273. 
     The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

     Article • The Lancet, August 2019, Elsevier

     Dr Benjamin Mullish

274. 
     Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: ‘A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enter...

     Article • Clinical Microbiology and Infection, July 2019, Elsevier

     Dr Benjamin Mullish

275. 
     BAUS 2019 Abstract Book

     Article • Journal of Clinical Urology, June 2019, SAGE Publications

     Dr Benjamin Mullish

276. 
     Recurrent bacteraemia following variceal haemorrhage

     Article • Gut, June 2019, BMJ

     Dr Benjamin Mullish

277. 
     In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation

     Article • Gut Microbes, May 2019, Taylor & Francis

     Dr Tanya M Monaghan, Dr Benjamin Mullish

278. 
     621 – Fecal Microbiota Transplantation for the Treatment of Obesity: A Randomized, Placebo-Controlled Pilot Trial

     Article • Gastroenterology, May 2019, Elsevier

     Dr Benjamin Mullish

279. 
     7 – The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation

     Article • Gastroenterology, May 2019, Elsevier

     Dr Benjamin Mullish

280. 
     Mo1953 – Growth Inhibition of Clostridioides Difficile by Short and Medium Chain Fatty Acids

     Article • Gastroenterology, May 2019, Elsevier

     Dr Benjamin Mullish

281. 
     Sa1924 – Effect of Short Chain Fatty Acids on Gut-Brain Axis Using a Microglial Cell Model

     Article • Gastroenterology, May 2019, Elsevier

     Dr Benjamin Mullish

282. 
     MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY

     Article • The Journal of Urology, April 2019, Wolters Kluwer Health

     Dr Benjamin Mullish

283. 
     PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis

     Article • Journal of Hepatology, April 2019, Elsevier

     Dr Benjamin Mullish, Dr Vishal C Patel

284. 
     SAT-294-Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD

     Article • Journal of Hepatology, April 2019, Elsevier

     Dr Benjamin Mullish

285. 
     THU-306-Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?

     Article • Journal of Hepatology, April 2019, Elsevier

     Dr Benjamin Mullish

286. 
     THU-331-Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume

     Article • Journal of Hepatology, April 2019, Elsevier

     Dr Benjamin Mullish

287. 
     Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non‐alcoholic fatty liver disease – authors’ reply

     Article • Alimentary Pharmacology & Therapeutics, March 2019, Wiley

     Dr Benjamin Mullish

288. 
     Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume

     Article • Alimentary Pharmacology & Therapeutics, March 2019, Wiley

     Dr Benjamin Mullish

289. 
     Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of faecal Microbiota transplantation (FMT) as a treatment modality

     Article • European Urology Supplements, March 2019, Elsevier

     Dr Benjamin Mullish

290. 
     Current and future targets for faecal microbiota transplantation

     Article • Human Microbiome Journal, March 2019, Elsevier

     Dr Benjamin Mullish

291. 
     Current and future pharmacological therapies for managing cirrhosis and its complications

     Article • World Journal of Gastroenterology, February 2019, Baishideng Publishing Group Co., Limited (formerly WJG Press)

     Dr Benjamin Mullish

292. 
     Liver Biopsy

     Article • February 2019, Wiley

     Dr Benjamin Mullish

293. 
     Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection

     Article • Gut, February 2019, BMJ

     Dr Benjamin Mullish

294. 
     Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial

     Article • The American Journal of Gastroenterology, January 2019, Wolters Kluwer Health

     Dr Benjamin Mullish

295. 
     The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease

     Article • Therapeutic Advances in Gastroenterology, January 2019, SAGE Publications

     Dr Benjamin Mullish

296. 
     Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease

     Article • Therapeutic Advances in Gastroenterology, January 2019, SAGE Publications

     Dr Benjamin Mullish

297. 
     1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae

     Article • Open Forum Infectious Diseases, November 2018, Oxford University Press (OUP)

     Dr Benjamin Mullish

298. 
     Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota

     Article • Gastroenterology, November 2018, Elsevier

     Dr Benjamin Mullish

299. 
     Non-alcoholic fatty liver disease and cardiovascular risk: an update

     Article • Expert Review of Gastroenterology & Hepatology, October 2018, Taylor & Francis

     Dr Benjamin Mullish

300. 
     Bile Acid Profiles are Not Altered by Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis: Category Award (Liver): Presidential Poster Award

     Article • The American Journal of Gastroenterology, October 2018, Wolters Kluwer Health

     Dr Benjamin Mullish

301. 
     Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines

     Article • Journal of Hospital Infection, October 2018, Elsevier

     Dr Benjamin Mullish

302. 
     Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease

     Article • Methods, October 2018, Elsevier

     Dr Benjamin Mullish

303. 
     Posters (Abstracts 301–2389)

     Article • Hepatology, October 2018, Wolters Kluwer Health

     Dr Benjamin Mullish

304. 
     Publisher’s Note: Poster Abstract

     Article • Open Forum Infectious Diseases, October 2018, Oxford University Press (OUP)

     Dr Benjamin Mullish

305. 
     Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway

     Article • Gut Microbes, September 2018, Taylor & Francis

     Dr Tanya M Monaghan, Dr Benjamin Mullish

306. 
     The implementation of omics technologies in cancer microbiome research

     Article • ecancermedicalscience, September 2018, Cancer Intelligence

     Dr Benjamin Mullish

307. 
     Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study

     Article • Scandinavian Journal of Gastroenterology, September 2018, Taylor & Francis

     lawrence penez, Dr Benjamin Mullish

308. 
     Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant

     Article • Hepatology, September 2018, Wolters Kluwer Health

     Dr Benjamin Mullish

309. 
     The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

     Article • Journal of Hospital Infection, September 2018, Elsevier

     Dr Benjamin Mullish

310. 
     The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

     Article • Gut, August 2018, BMJ

     Dr Benjamin Mullish

311. 
     0503 - A novel route for controlling Clostridioides difficile growth via bile acid and short chain fatty acid modulation

     Article • August 2018, Morressier

     Dr Benjamin Mullish

312. 
     Clostridium difficile infection and antibiotic-associated diarrhoea

     Article • Clinical Medicine, June 2018, Elsevier

     Dr Benjamin Mullish

313. 
     IDDF2018-ABS-0056 Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study

     Article • June 2018, BMJ

     Dr Benjamin Mullish

314. 
     PWE-052 Long term outcomes of initial IFX therapy for inflammatory pouch pathology: a multi-centre retrospective study

     Article • June 2018, BMJ

     Dr Benjamin Mullish

315. 
     Letter: improvements in mental health after faecal microbiota transplantation—an underexplored treatment‐related benefit?

     Article • Alimentary Pharmacology & Therapeutics, May 2018, Wiley

     Dr Benjamin Mullish

316. 
     24 - A Novel Route to Controlling Clostridioides Difficile Growth via Short Chain Fatty Acid and Bile Acid Modulation

     Article • Gastroenterology, May 2018, Elsevier

     Dr Benjamin Mullish

317. 
     25 - Microbiome and Metabolic Markers of Clostridium Difficile Recurrance

     Article • Gastroenterology, May 2018, Elsevier

     Dr Benjamin Mullish

318. 
     Tu1894 - Potential Motivators and Deterents for Stool Donors: A Multicenter Study

     Article • Gastroenterology, May 2018, Elsevier

     Dr Benjamin Mullish

319. 
     A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease

     Article • Journal of Hepatology, April 2018, Elsevier

     Dr Benjamin Mullish

320. 
     Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia‐related portal vein thrombosis

     Article • Journal of Gastroenterology and Hepatology, January 2018, Wiley

     Dr Benjamin Mullish

321. 
     P141 Infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study

     Article • Journal of Crohn s and Colitis, January 2018, Oxford University Press (OUP)

     Dr Benjamin Mullish

322. 
     Posters (Abstracts 264-2239)

     Article • Hepatology, October 2017, Wiley

     Raghubendra Dagur, Dr Benjamin Mullish

323. 
     Comparative epidemiology of Clostridium difficile infection: England and the USA

     Article • International Journal for Quality in Health Care, September 2017, Oxford University Press (OUP)

     Dr Benjamin Mullish

324. 
     Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

     Article • Hepatology, August 2017, Wolters Kluwer Health

     Dr Benjamin Mullish

325. 
     Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality

     Article • British Journal of Pharmacology, July 2017, Springer Science + Business Media

     Dr Benjamin Mullish

326. 
     PWE-093 Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine: histological images in patients with non-alcoholic fatty liver disease

     Article • June 2017, BMJ

     Dr Benjamin Mullish

327. 
     PWE-094 The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease

     Article • June 2017, BMJ

     Dr Benjamin Mullish

328. 
     OC-063 Gut microbiota-host bile acid metabolism interactions in clostridium difficile infection: the explanation for the efficacy of faecal microbiota transplantation?

     Article • June 2017, BMJ

     Dr Benjamin Mullish

329. 
     Anticoagulation in chronic liver disease

     Article • Journal of Hepatology, June 2017, Elsevier

     Dr Benjamin Mullish

330. 
     Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes

     Article • Gastroenterology, April 2017, Elsevier

     Dr Benjamin Mullish

331. 
     National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK

     Article • Journal of Hospital Infection, April 2017, Elsevier

     Dr Benjamin Mullish

332. 
     The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease

     Article • Journal of Hepatology, January 2017, Elsevier

     Dr Benjamin Mullish

333. 
     Meeting update: faecal microbiota transplantation––bench, bedside, courtroom?

     Article • Frontline Gastroenterology, November 2016, BMJ

     Dr Benjamin Mullish

334. 
     Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance

     Article • BMJ, September 2016, BMJ

     Dr Benjamin Mullish

335. 
     OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom

     Article • Gut, June 2016, BMJ

     Dr Benjamin Mullish

336. 
     PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?

     Article • Gut, June 2016, BMJ

     Dr Benjamin Mullish

337. 
     Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces

     Article • Analytical Chemistry, April 2016, American Chemical Society (ACS)

     Dr Benjamin Mullish

338. 
     Cardiology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

339. 
     Clinical haematology and oncology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

340. 
     Clinical sciences

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

341. 
     Dermatology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

342. 
     Endocrinology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

343. 
     Gastroenterology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

344. 
     Geriatric medicine

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

345. 
     Infectious diseases and GUM

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

346. 
     Nephrology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

347. 
     Neurology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

348. 
     Ophthalmology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

349. 
     Psychiatry

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

350. 
     Respiratory medicine

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

351. 
     Rheumatology

     Article • January 2016, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

352. 
     Obstacles to establishing an NHS faecal transplant programme

     Article • BMJ, November 2015, BMJ

     Dr Benjamin Mullish

353. 
     Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authors’ reply

     Article • Alimentary Pharmacology & Therapeutics, April 2015, Wiley

     Dr Benjamin Mullish

354. 
     Weight loss in a man from West Africa

     Article • Gut, March 2015, BMJ

     Dr Benjamin Mullish

355. 
     Global patterns of cardia and non-cardia gastric cancer incidence in 2012

     Article • Gut, March 2015, BMJ

     Dr Benjamin Mullish

356. 
     Case 25-2014: A Man with Ulcerative Colitis and Bloody Diarrhea

     Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2014, New England Journal of Medicine (NEJM/MMS)

     Dr Benjamin Mullish

357. 
     Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection

     Article • QJM, September 2014, Oxford University Press (OUP)

     Dr Benjamin Mullish

358. 
     Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

     Article • Alimentary Pharmacology & Therapeutics, September 2014, Wiley

     Dr Benjamin Mullish

359. 
     Faecal microbiota transplantation

     Article • BJS, May 2014, Oxford University Press (OUP)

     Dr Benjamin Mullish

360. 
     Low Incidence Of Venous Thromboembolism In Mobile Populations

     Article • Value in Health, May 2014, Elsevier

     Dr Benjamin Mullish

361. 
     Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature

     Article • BMC Gastroenterology, April 2014, Springer Science + Business Media

     Dr Benjamin Mullish

362. 
     P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS

     Article • Journal of Hepatology, April 2014, Elsevier

     Dr Benjamin Mullish

363. 
     MRCP Part 1: 400 BOFs

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

364. 
     Cardiology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

365. 
     Clinical pharmacology, therapeutics and toxicology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

366. 
     Clinical sciences

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

367. 
     Dermatology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

368. 
     Endocrinology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

369. 
     Gastroenterology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

370. 
     Haematology and oncology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

371. 
     Neurology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

372. 
     Ophthalmology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

373. 
     Psychiatry

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

374. 
     Renal medicine

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

375. 
     Respiratory medicine

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

376. 
     Rheumatology

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

377. 
     Tropical, infectious and sexually transmitted diseases

     Article • January 2013, Jaypee Brothers Medical Publishing

     Dr Benjamin Mullish

378. 
     Shoulder pain and dysphagia with an unexpected cause

     Article • BMJ Case Reports, February 2011, BMJ

     Dr Benjamin Mullish

379. 
     Ascites

     Article • BMJ, February 2010, BMJ

     Dr Benjamin Mullish